Small Anim News Today

Canalevia®-CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDASAN FRANCISCO, CA / ACCESSWIRE / May 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or

91.67% of respondents to a question asking how they see themselves using the product in the future indicated they plan on increasing use of Canalevia®-CA1 over timeCanalevia-CA1, Jaguar Health's FDA Conditionally

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDAIn December 2022, FDA increased the maximum number of dogs that can be treated annually with a

Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDASAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar

Canalevia-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDAVeterinary oncologists

Canalevia-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDAU.S. veterinarians, veterinary

Canalevia™-CA1, which received conditional approval from the FDAon December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA ... | March 1, 2022

2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure

Canalevia-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from FDAU.S. veterinarians, veterinary